|1.||Poulsen, Birgitte Klindt: 1 article (01/2015)|
|2.||Hvas, Anne-Mette: 1 article (01/2015)|
|3.||Kierulf-Lassen, Casper: 1 article (01/2015)|
|4.||Roccatello, D: 1 article (11/2011)|
|5.||Giachino, O: 1 article (11/2011)|
|6.||Bazzan, M: 1 article (11/2011)|
|7.||Vaccarino, A: 1 article (11/2011)|
|8.||Colagrande, P: 1 article (11/2011)|
|9.||Bernardi, F: 1 article (11/2011)|
|10.||Stella, S: 1 article (11/2011)|
11/01/2011 - "Factor IX propeptide mutation and life threatening bleeding."
07/01/1997 - "Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy."
01/26/2015 - "These findings were suggestive of a mutation in the factor IX propeptide, but thrombocytopathy induced by selective serotonin re-uptake inhibitors could have worsened the bleeding. "
01/01/2003 - "A founder mutation of the factor IX propeptide constitutes a genetic predisposition to bleeding in patients put on coumarins. "
11/01/2005 - "Increased risk of bleeding during oral anticoagulant (OA) treatment may be related to mutations in the precursor of coagulation factor IX. Missense mutations at Ala-10 (Ala-10Thre and Ala-10Val) in the factor IX propeptide lead to impaired carboxylation of factor IX. When patients carrying these mutations are treated with coumarins, functional factor IX levels decrease significantly, leading to an excessively prolonged activated partial thromboplastin time (aPTT) and an increased bleeding risk. "
|2.||Venous Thrombosis (Deep-Vein Thrombosis)
|3.||Genetic Predisposition to Disease (Genetic Predisposition)
|4.||Blood Platelet Disorders (Thrombocytopathy)
|3.||Serotonin (5 Hydroxytryptamine)
|4.||Factor IX (PTC)